MedTrace Logo

The Effect of Diflunisal on Familial Transthyretin Amyloidosis

NCT01432587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2015-08-24

No results posted yet for this study

Summary

An ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue their treatment. The investigators want to continue to monitor the effect of the drug on transthyretin (TTR) amyloidosis in an open label observational study.

Primary endpoint will be a composite score of the manifestations of the disease (Kumamoto scale) and secondary end points will be measurements of neurological impairment, heart involvement and nutritional status.

Conditions

  • Amyloidosis

Interventions

DRUG

Diflunisal

Film-coated tablet, 250 mg twice daily, orally for approximately 2 years

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Ole B Suhr, MD PhD · Dept of Clinical Medicine and public Health, Umeå University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01432587 on ClinicalTrials.gov